-

$undefined

N/A

(N/A)

Sonnet BioTherapeutics :SONN Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease.

Location: | Industry: | Sector:


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-335.9K

Cash

4.862M

Avg Qtr Burn

-2.107M

Short % of Float

3.84%

Insider Ownership

1.57%

Institutional Own.

3.06%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.